Faisal Mehmud
Pfizer (United Kingdom)(GB)
Publications by Year
Research Areas
Renal cell carcinoma treatment, Economic and Financial Impacts of Cancer, Cancer Genomics and Diagnostics, Atrial Fibrillation Management and Outcomes, Multiple and Secondary Primary Cancers
Most-Cited Works
- → Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study(2014)438 cited
- → Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study(2008)173 cited
- → Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)—PISCES study, NCT 01064310.(2012)67 cited
- → Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first‐line sunitinib: a medical chart review across ten centers in five European countries(2014)61 cited
- → Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review(2013)36 cited
- → Relationship between plasma pazopanib concentration and incidence of adverse events in renal cell carcinoma.(2011)19 cited
- → Suspected Cancer Symptoms and Blood Test Results in Primary Care Before a Diagnosis of Lung Cancer: A Case–Control Study(2019)15 cited
- → Factors associated with non-prescription of oral anticoagulant treatment in non-valvular atrial fibrillation patients with dementia: a CPRD–HES study(2020)15 cited
- → Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients with Advanced Renal Cell Carcinoma Treated with Pazopanib(2015)13 cited